Nahla M. Badr

Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Vit D mitigates metabolic syndrome-induced hepatic damage via antioxidant, anti-inflammatory, and AMPK/PI3K signaling pathways in rats.

Vit D mitigates metabolic syndrome-induced hepatic damage via antioxidant, anti-inflammatory, and AMPK/PI3K signaling pathways in rats.

Journal: Archives of physiology and biochemistry

Published: October 21, 2025

An Insight into Prognostic Impact of TIPE2 & CD36 Immunohistochemical Expression in Urothelial Carcinoma.

An Insight into Prognostic Impact of TIPE2 & CD36 Immunohistochemical Expression in Urothelial Carcinoma.

Journal: Iranian journal of pathology

Published: May 25, 2024

Evaluation of the diagnostic utility of NCOA3, Maspin and VHL protein expression in pancreatic ductal adenocarcinoma: An immunohistochemical study.

Evaluation of the diagnostic utility of NCOA3, Maspin and VHL protein expression in pancreatic ductal adenocarcinoma: An immunohistochemical study.

Journal: Annals of diagnostic pathology

Published: May 02, 2024

Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers.

Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers.

Journal: International journal of molecular sciences

Published: April 19, 2024

Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.

Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.

Journal: Histopathology

Published: November 25, 2023

Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International Study.

Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International Study.

Journal: Cancers

Published: November 01, 2022

Tspan6 stimulates the chemoattractive potential of breast cancer cells for B cells in an EV- and LXR-dependent manner.

Tspan6 stimulates the chemoattractive potential of breast cancer cells for B cells in an EV- and LXR-dependent manner.

Journal: Cell reports

Published: June 06, 2022

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.

Journal: Ecancermedicalscience

Published: February 04, 2022

Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence.

Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: November 22, 2021

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: October 26, 2020

Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer: implications for clinical practice.

Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer: implications for clinical practice.

Journal: Histopathology

Published: October 25, 2020

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.

Journal: British journal of cancer

Published: October 18, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026